# Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer.

> **NCT05425550** · NA · TERMINATED · sponsor: **Palleos Healthcare GmbH** · enrollment: 196 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DEVICE:** medidux™ app

## Key facts

- **NCT ID:** NCT05425550
- **Lead sponsor:** Palleos Healthcare GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-29
- **Primary completion:** 2025-06-05
- **Final completion:** 2025-06-05
- **Target enrollment:** 196 (ACTUAL)
- **Why stopped:** The study was discontinued due to low recruitment rates. Despite various measures, such as training courses and workshops, recruitment rates could not be improved in the long term.
- **Last updated:** 2025-09-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05425550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05425550, "Evaluation of the Medidux™ Digital Health Application in Patients With HER2-positive Breast Cancer.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05425550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*